Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07023666
PHASE2

Early Screening and Treatment of Heart Complication in Sickle Cell Disease

Sponsor: Inova Health Care Services

View on ClinicalTrials.gov

Summary

This study tests whether early heart screening and treatment for iron overload in subjects with sickle cell disease can prevent heart problems and reduce hospitalizations.

Official title: Early Detection and Management of Cardiac Iron Overload in Sickle Cell Disease Using Multimodal Imaging for Improved Clinical Outcomes

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2025-10-07

Completion Date

2027-06-30

Last Updated

2025-10-14

Healthy Volunteers

No

Interventions

DRUG

Deferoxamine

Deferoxamine is used to reduce excess iron accumulation after monitoring iron levels. Adjustment to therapy will be based on iron burden assessments throughout the study duration.

DRUG

Deferasirox

Deferasirox is used for iron chelation therapy based on iron burden assessment throughout the study.

DRUG

Deferiprone

Deferiprone is used for iron chelation therapy used throughout the study.

DEVICE

Echocardiography

This device uses ultrasound waves to create images of heart to help evaluate the heart's structure and function. This allows the detection of abnormalities of heart due to iron overload through out the study.

DEVICE

Electrocardiogram (ECG)

The Electrocardiogram (ECG) device records the electrical activity of the heart. It is crucial for identifying arrhythmias and conduction abnormalities, which can be exacerbated by iron accumulation in the heart.

Locations (2)

Inova Schar Cancer

Fairfax, Virginia, United States

Inova Health Care Service

Falls Church, Virginia, United States